Page 58 - Read Online

Page 168 Elton et al. Cancer Drug Resist 2020;3:161-70 I http://dx.doi.org/10.20517/cdr.2019.117

DECLARATIONS
Authors’ contributions
Made substantial contributions to conception, design, performed data analysis, and interpretation: Elton
TS, Ozer HG, Yalowich JC

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by the National Institutes of Health National Cancer Institute (Grant R01
CA226906-01A1).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep’s clothing. Nucleic Acids Res 2009;37:738-48.
2. Vos SM, Tretter EM, Schmidt BH, Berger JM. All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev
Mol Cell Biol 2011;12:827-41.
3. Chen SH, Chan NL, Hsieh TS. New mechanistic and functional insights into DNA topoisomerases. Annu Rev Biochem 2013;82:139-70.
4. Pommier Y, Sun Y, Huang SN, Nitiss JL. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat
Rev Mol Cell Biol 2016;17:703-21.
5. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9:338-50.
6. Pommier Y, Marchand C. Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov 2011;11:25-36.
7. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013;8:82-95.
8. Delgado JL, Hsieh CM, Chan NL, Hiasa H. Topoisomerases as anticancer targets. Biochem J 2018;475:373-98.
9. Economides MP, McCue D, Borthakur G, Pemmaraju N. Topoisomerase II inhibitors in AML: past, present, and future. Expert Opin
Pharmacother 2019;20:1637-44.
10. Edwardson DW, Narendrula R, Chewchuk S, Mispel-Beyer K, Mapletoft JPJ, et al. Role of drug metabolism in the cytotoxicity and
clinical efficacy of anthracyclines. Curr Drug Metab 2015;16:412-26.
11. Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin 2018;68:116-32.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer (Version
1.2020). Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf [Last accessed on 19 Feb 2020]
13. Zhao H, Ren D, Liu H, Chen J. Comparison and discussion of the treatment guidelines for small cell lung cancer. Thorac Cancer
2018;9:769-74.
14. Greene J, Hennessy B. The role of anthracyclines in the treatment of early breast cancer. J Oncol Pharm Pract 2015;21:201-12.
15. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, et al. Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090,
NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 2017;35:2647-55.
16. Owattanapanich W, Owattanapanich N, Kungwankiattichai S, Ungprasert P, Kuchutrakool T. Efficacy and toxicity of idarubicin versus
high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: a systematic review and meta-analysis. Clin
Lymphoma Myeloma Leuk 2018;18:814-21.e3.
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (Version
2.2020). Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf [Last accessed on 19 Feb 2020]
18. Burgess DJ, Doles J, Zender L, Xue W, Ma B, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc
Natl Acad Sci U S A 2008;105:9053-58.
19. Pilati P, Nitti D, Mocellin S. Cancer resistance to type II topoisomerase inhibitors. Curr Med Chem 2012;19:3900-06.